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Outcome measures are powerful tools in a clinician’s arma-
mentarium. These instruments capture clinical information 
and may supplement clinical judgment in order to optimize 
management approach, medical treatment, and referrals to 
other appropriate health-care providers. They may shed light 
on psychosocial issues while providing insight into gaps in 
understanding not previously considered by the clinician or 
the patient. These tools highlight variability between diseases 
when using the same scoring system and may influence clini-
cal guideline recommendations. Additionally, these instru-
ments may influence policy directed toward allocation of 
limited resources, playing a significant role in future strate-
gies aimed at cost-effectiveness.
BacKGrOund
Scores, scales, profiles, and indexes are all examples of 
outcome measures. Outcome measures typically attempt 
to quantify either (i) clinical disease severity or (ii) patient-
reported outcomes. Clinical disease severity–assessment 
tools gauge the global extent of disease, such as percentage 
of body surface area affected, physician global assessment, 
or the characteristics of isolated skin lesions. More disease-
specific tools are the Psoriasis Area and Severity Index and 
the Scoring Atopic Dermatitis tool. Another group of tools 
focuses on patient-reported outcomes such as health-
related quality of life (HRQoL), assessing the impact of a 
disease on patients’ lives or evaluating treatment prefer-
ence/satisfaction. These instruments may be generic, allow-
ing comparison across diseases (e.g., SF-36), dermatology 
specific (e.g., Dermatology Quality of Life index or 
Skindex), disease specific, or concept specific (e.g., stigma-
tization or anxiety). Figure 1 demonstrates the relationships 
among clinical disease severity measures, HRQoL tools, 
and therapeutic intervention data.
hOW are OuTcOme measures ValidaTed?
Analytical treatment of an instrument has acquired the name 
“validation,” and it is the widely accepted method for evalu-
ating the integrity of an instrument. The term “validation” is 
technically inappropriate because “validity” is only one of 
the axes or properties weighed. The evaluation of an instru-
ment involves testing many properties, including validity, 
structure, reliability, and responsiveness.
The outcome measure must first be developed (usually a 
questionnaire) and administered. Next, the tool undergoes 
property testing (statistical analysis) to determine the integrity of 
the tool based on the answers that are generated from initial test 
administration (Weller et al., 2012). Once this is accomplished 
with desirable results, the instrument can be used as a qualita-
tive measure for use in a study and/or as a clinical decision–
making tool.
deVelOpmenT
item generation
Items are questions or statements pertaining to the topic or 
disease condition for use within the instrument. Items may be 
generated in a variety of manners. “Exploratory interviews” by 
psychologists with a heterogeneous cohort of patients affected 
by the condition may be utilized to elicit significant and relevant 
issues of interest. Additional strategies involve systematic litera-
ture reviews of similar studies and consultation with colleagues 
and experts in the disease-specific field. This process generates 
a pool of issues that must be phrased and checked with the 
patients to determine whether the constructed items are inter-
pretable and unambiguous. Items are formatted in question or 
statement form, followed by answer choices. Commonly chosen 
is the Likert 5-point scale, with answer choices such as “never”
/“rarely”/“sometimes”/“often”/“always” or “strongly disagree”/ 
“disagree”/“neutral”/“agree”/“strongly agree.” It is also optional 
to limit these answers by instructing the patient to answer only 
the questions based on a specified time frame, such as the previ-
ous week, month, or year (Weller et al., 2012).
adVanTaGes OF OuTcOme measures
•  Outcome measures quantify clinical disease 
severity and patient-reported outcomes.
•  They are judged on the basis of their behavior 
when tested for certain properties, including 
structure, validity, reliability, and responsiveness.
LIMITATIONS 
•  No gold standard currently exists for comparing tools.
1Albert Einstein College of Medicine, Division of Dermatology, Department of Medicine, Bronx, New York, USA and 2 Department of Dermatology, 
Erasmus Medical Center, Rotterdam, The Netherlands
Correspondence: Karthik Krishnamurthy, 1400 Pelham Parkway South, Building 1, Suite 4W-4D, Bronx, New York 10461, USA. E-mail: kkderm@gmail.com
research Techniques made simple  
research Techniques made simple  
2 Journal of Investigative Dermatology (2013), Volume 133 © 2013 The Society for Investigative Dermatology
1997). Ideally, items load uniquely on one factor (dimen-
sion). If an item loads on multiple factors or on none of the 
extracted factors (so called “item complexity”), the item is 
best discarded because its significance cannot be directly 
attributed to only one dimension, making interpretation of 
its score ambiguous. The dimensionality of an instrument can 
also be tested using models based on the item response the-
ory, of which the Rasch analysis is the most commonly used 
model in dermatology (Wright, 1996).
For instance, the Skindex includes constructs such as physi-
cal limitations and discomfort within the physical domain. 
Dimensions within the psychosocial domain include cognitive, 
social, and emotional disruptions, with the emotional dimen-
sion being further characterized by the constructs of depression, 
fear, embarrassment, and anger (Figure 2) (Chren et al., 1996).
Items must be loaded onto a specific domain for instru-
ment results to be appropriately interpreted. For example, the 
Skindex item “My skin hurts” is loaded onto the “discomfort” 
category, a component of the physical domain. Conversely, 
“I think about my skin condition” is loaded on the “cogni-
tive” category, a psychosocial domain. Items may be loaded 
onto a construct in a variety of ways, ranging from objective 
to subjective.
Validity
The validity of an instrument is the extent to which it measures 
what it is intended to measure. Rather than a single gold stan-
dard, there are several methods with which to assess validity.
Content validity refers to the adequacy of the instrument 
to address all relevant items within a construct; this can be 
evaluated by the instrument respondents (e.g., patient). When 
assessed by experts, this is termed “face validity.”
Convergent validity is achieved when a tool correlates well 
with tools that are supposed to measure the same underlying 
construct (e.g., a new tool assessing HRQoL in atopic eczema 
patients showed results similar to those obtained using an 
existing HRQoL tool). The statistical test used is the correlation 
coefficient.
Construct validity is tested by hypothesizing that different 
groups of patients show differences in scores as expected. For 
example, patients with severe disease should exhibit higher 
levels of HRQoL impairment than those for patients with mild 
disease. If this is confirmed by the outcome-measure tool, it will 
suggest optimal construct validity (Prinsen et al., 2013).
reliability
Test–retest reliability evaluates the consistency of the score when 
the instrument is administered to the same person at different 
times, with the interval being short enough that the disease con-
dition is unlikely to have changed. Intraclass correlation coef-
ficients are used to determine this aspect of reliability, with 1.0 
showing perfect correlation. Generally, scores greater than 0.7 
are considered acceptable (Spuls et al., 2010).
Internal consistency can be tested after one applica-
tion of an instrument and examines the degree to which the 
set of items measures the same construct; this is measured 
by Cronbach’s α test. For example, an α < 0.7 suggests that 
the item is not highly correlated with the other items in the 
item reduction
During this stage, the large set of items is administered to 
a large number of target patients to determine which items 
carry the largest impact factor. One method involves deter-
mining the “frequency” of each item by asking patients 
whether they have experienced the problem described in the 
item over the specified time frame. The percentage of “yes” 
answers becomes the frequency. The patients are also asked 
to determine the “importance” on a 5-point scale. The prod-
uct of the frequency and importance is defined as the impact 
factor. The higher the impact factor, the more relevant the 
item. Items with low impact factors can be reduced or elimi-
nated from the instrument (Weller et al., 2012).
prOperTY TesTinG (ValidaTiOn)
Because no gold standard exists against which to compare 
a tool, tools are judged on the basis of their behavior when 
tested for certain properties, such as structure, validity, 
reliability, and responsiveness. For example, for assessing 
HRQoL, the SF-36 and Skindex behave “well” when 
property-tested (Both et al., 2007).
structure
Many tools recognize that specific items affect specific 
aspects (or constructs) of a patient’s life, namely, constructs 
within the physical domain versus the psychosocial domain; 
this can be further differentiated in subjective and objective 
impact (Muldoon et al., 1998). The structure of a question-
naire is important because it assesses whether the questions 
all address the same underlying construct (i.e., impact). 
Ultimately, for item/question scores to be grouped together 
and summed, the items should be unidimensional (i.e., mea-
sure the same underlying construct). In classic test theory, 
exploratory factor analysis is used as an objective method 
and assumes no a priori hypotheses regarding the construct 
on which an item should be loaded. It allows statistical 
analysis to group and associate items, with domains based 
on underlying patterns and relationships, without bias (Norris 
and Lecavalier, 2009; Fabrigar et al., 1999; Finch and West, 
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Figure 1. clinical outcomes. Health-related quality-of-life (HRQoL) tools, 
the relationship among clinical disease severity–assessment measures,  and 
therapeutic intervention data. Illustration by Tamar Nijsten.
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scale, suggesting it measures a different aspect of the disease. 
Conversely, an α > 0.9 suggests item redundancy, and the con-
struct is being overemphasized and overrepresented within the 
instrument (Prinsen et al., 2013).
Responsiveness refers to the instrument’s capability to 
change when the patient experiences a change in disease state. 
Responsiveness addresses whether a tool is sensitive enough 
to detect changes in patients. For example, the score should 
be lower after a successful therapeutic intervention than it was 
prior to treatment. The important question is whether the change 
in impairment reflects a statistically significant change while 
actually affecting the patient. To assess this, the minimal clinical 
important difference can be estimated (Revicki et al., 2008).
Response distribution assesses whether the entire range of the 
item scores is being utilized. If more than 70% of patients score 
an item “0” (or any other score), then this item may not discrimi-
nate between patients and may be removed from the scale.
Overall, the distribution of scores can also be measurement 
indicators. For example, the Psoriasis Area and Severity Index 
instrument curve is skewed right, underrepresenting patients 
who suffer from mild disease because the instrument is not as 
sensitive to detection of disease in this range (Spuls et al., 2010).
Finally, other axes of instrument evaluation lie in identifying 
biases based on culture and language, as well as practical issues 
ranging from respondent burden (is the tool too long?) to admin-
istrative burdens, e.g., means of administration (verbal, over the 
phone, via computer) and data collection (Spuls et al., 2010).
There are currently no guidelines for development or 
appropriate testing of intended health measurement within 
an outcome measure. The Consensus-based Standards for the 
Selection of Health Measurement Instruments study represents 
initial research in the development of a provider checklist to 
address this need in assessing different health-related, patient-
reported outcomes using the Delphi procedure. This process 
includes sequential questionnaires, or “rounds,” with controlled 
feedback to gain consensus by a group of experts. It is favor-
able where there is a lack of empirical evidence, yet it is able to 
incorporate responses from leaders in many health-care fields 
of expertise (Mokkink et al., 2010). Thus, health-care providers 
may use this checklist to select appropriate measurement tools 
for patient feedback and optimal health-care outcomes.
WhY is This impOrTanT in dermaTOlOGY?
With more than 50 proposed outcome measures for patients 
with psoriasis, how can dermatologists determine which mea-
surement tool is appropriate for their patients (Spuls et al., 2010)? 
The health-care provider must understand how to administer, as 
well as interpret the results of, an outcome measure for effective 
utilization while recognizing the limitations of each tool. Factors 
including study setting, disease manifestation, and patient type 
must also be considered when choosing an optimal outcome 
measure. Provider exposure and training are critical to a better Figure 2. conceptual framework representing the effects of skin disease on 
quality of life. This hypothesis was based on literature review and directed 
interviews with patients with skin disease and clinicians who care for them. 
The boxes with double borders indicate constructs addressed by the eight 
scales of the Skindex. Adapted from Chren et al. (1996).
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Effect of
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1.  Which of the following is nOT an example of an  
outcome measure?
A. Score.
B. Scale.
C. Profile.
D.  Index.
E. Table.
2.  Which of the following is nOT a property used to 
test the behavior of an outcome measurement tool?
A.  Validity.
B.  Structure.
C. Responsiveness.
D. Reliability.
E. Sensibility.
3.  Which of the following statements regarding  
outcome measures is false?
A.  The PASI remains the gold standard by which all 
other psoriasis tools are judged.
B.  The COSMIN checklist is an attempt to standardize 
development and reporting of outcome measures.
C.  Outcome measures are used to quantify clinical 
disease severity and patient-reported outcomes.
D.  Items that load onto multiple constructs are best 
eliminated from the instrument.
E.  In the Skindex, the emotional dimension is further 
subdivided into the constructs of depression, fear, 
embarrassment, and anger.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME Credit. To take the quiz, 
with or without CME credit, follow the link under the "CME CREDIT" header.
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understanding of outcome measures and their role in determin-
ing the extent of disease burden in order to assist dermatologists 
in providing optimal patient care.
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other teaching exercises are available at http://dx.doi.org/10.1038/jid.2013.332.
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